For: | Miao RY, Zhao HT, Yang HY, Mao YL, Lu X, Zhao Y, Liu CN, Zhong SX, Sang XT, Huang JF. Postoperative adjuvant antiviral therapy for hepatitis B/C virus-related hepatocellular carcinoma: A meta-analysis. World J Gastroenterol 2010; 16(23): 2931-2942 [PMID: 20556841 DOI: 10.3748/wjg.v16.i23.2931] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v16/i23/2931.htm |
Number | Citing Articles |
1 |
2018 Korean Liver Cancer Association–National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. Korean Journal of Radiology 2019; 20(7): 1042 doi: 10.3348/kjr.2019.0140
|
2 |
Liping Chen, Qi Zhang, Wenjun Chang, Yan Du, Hongwei Zhang, Guangwen Cao. Viral and host inflammation-related factors that can predict the prognosis of hepatocellular carcinoma. European Journal of Cancer 2012; 48(13): 1977 doi: 10.1016/j.ejca.2012.01.015
|
3 |
Wei Zhang, Bixiang Zhang, Xiao-ping Chen. Adjuvant treatment strategy after curative resection for hepatocellular carcinoma. Frontiers of Medicine 2021; 15(2): 155 doi: 10.1007/s11684-021-0848-3
|
4 |
Wenqian Qi, Qian Zhang, Yan Xu, Xu Wang, Fan Yu, Yonggui Zhang, Ping Zhao, Honghua Guo, Changyu Zhou, Zhe Wang, Yu Sun, Lin Liu, Wei Xuan, Jiangbin Wang. Peg‐interferon and nucleos(t)ide analogue combination at inception of antiviral therapy improves both anti‐HBV efficacy and long‐term survival among HBV DNA‐positive hepatocellular carcinoma patients after hepatectomy/ablation. Journal of Viral Hepatitis 2020; 27(4): 387 doi: 10.1111/jvh.13236
|
5 |
Su Jong Yu, Yoon Jun Kim. Hepatitis B viral load affects prognosis of hepatocellular carcinoma. World Journal of Gastroenterology 2014; 20(34): 12039-12044 doi: 10.3748/wjg.v20.i34.12039
|
6 |
Liang-He Yu, Nan Li, Shu-Qun Cheng. The Role of Antiviral Therapy for HBV-Related Hepatocellular Carcinoma. International Journal of Hepatology 2011; 2011: 1 doi: 10.4061/2011/416459
|
7 |
Augusto Villanueva, Virginia Hernandez-Gea, Josep M. Llovet. Medical therapies for hepatocellular carcinoma: a critical view of the evidence. Nature Reviews Gastroenterology & Hepatology 2013; 10(1): 34 doi: 10.1038/nrgastro.2012.199
|
8 |
Massimo Andreoni, Sergio Babudieri, Savino Bruno, Massimo Colombo, Anna L. Zignego, Vito Di Marco, Giovanni Di Perri, Carlo F. Perno, Massimo Puoti, Gloria Taliani, Erica Villa, Antonio Craxì. Current and future challenges in HCV: insights from an Italian experts panel. Infection 2018; 46(2): 147 doi: 10.1007/s15010-017-1093-1
|
9 |
Han-Yue Mo, Ying-Yang Liao, Xue-Mei You, Alessandro Cucchetti, Bao-Hong Yuan, Ru-Hong Li, Jian-Hong Zhong, Le-Qun Li, Teh-Ia Huo. Timely meta-analysis on the efficacy of adoptive immunotherapy for hepatocellular carcinoma patients after curative therapy. PLOS ONE 2017; 12(3): e0174222 doi: 10.1371/journal.pone.0174222
|
10 |
2022 KLCA-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. Korean Journal of Radiology 2022; 23(12): 1126 doi: 10.3348/kjr.2022.0822
|
11 |
C. C. N. Chong, G. L. H. Wong, V. W. S. Wong, P. C. T. Ip, Y. S. Cheung, J. Wong, K. F. Lee, P. B. S. Lai, H. L. Y. Chan. Antiviral therapy improves post‐hepatectomy survival in patients with hepatitis B virus‐related hepatocellular carcinoma: a prospective‐retrospective study. Alimentary Pharmacology & Therapeutics 2015; 41(2): 199 doi: 10.1111/apt.13034
|
12 |
Yanming Zhou, Xiaoying Si, Lupeng Wu, Xu Su, Bin Li, Zhiming Zhang. Influence of viral hepatitis status on prognosis in patients undergoing hepatic resection for hepatocellular carcinoma: a meta-analysis of observational studies. World Journal of Surgical Oncology 2011; 9(1) doi: 10.1186/1477-7819-9-108
|
13 |
Anna-Maria Tanase, Traian Dumitrascu, Simona Dima, Razvan Grigorie, Agnes Marchio, Pascal Pineau, Irinel Popescu. Influence of hepatitis viruses on clinico-pathological profiles and long-term outcome in patients undergoing surgery for hepatocellular carcinoma. Hepatobiliary & Pancreatic Diseases International 2014; 13(2): 162 doi: 10.1016/S1499-3872(14)60026-6
|
14 |
KLCA Korean Liver Cancer Association, NCC National Cancer Center. 2018 Korean Liver Cancer Association–National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. Gut and Liver 2019; 13(3): 227 doi: 10.5009/gnl19024
|
15 |
Liang-He Yu, Nan Li, Jie Shi, Wei-Xing Guo, Meng-Chao Wu, Shu-Qun Cheng. Does Anti-HBV Therapy Benefit the Prognosis of HBV-Related Hepatocellular Carcinoma Following Hepatectomy?. Annals of Surgical Oncology 2014; 21(3): 1010 doi: 10.1245/s10434-013-3320-z
|
16 |
Walaa Abdelhamed, Mohamed El-Kassas. Hepatocellular carcinoma recurrence: Predictors and management. Liver Research 2023; 7(4): 321 doi: 10.1016/j.livres.2023.11.004
|
17 |
Bulent Baran. Nucleos(t)ide analogs in the prevention of hepatitis B virus related hepatocellular carcinoma. World Journal of Hepatology 2015; 7(13): 1742-1754 doi: 10.4254/wjh.v7.i13.1742
|
18 |
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma. Journal of Liver Cancer 2023; 23(1): 1 doi: 10.17998/jlc.2022.11.07
|
19 |
Jian-Hong Zhong, Liang Ma, Le-Qun Li. Postoperative therapy options for hepatocellular carcinoma. Scandinavian Journal of Gastroenterology 2014; 49(6): 649 doi: 10.3109/00365521.2014.905626
|
20 |
Jing Xu, Li Liu, Hong Tang. Antiviral therapy for hepatitis B virus-associated hepatocellular carcinoma: Potential to reduce the tumor recurrence rates and/or improve overall survival. Medical Hypotheses 2011; 76(3): 457 doi: 10.1016/j.mehy.2010.12.016
|
21 |
Chiao-Fang Teng, Han-Chieh Wu, Ih-Jen Su, Long-Bin Jeng. Hepatitis B Virus Pre-S Mutants as Biomarkers and Targets for the Development and Recurrence of Hepatocellular Carcinoma. Viruses 2020; 12(9): 945 doi: 10.3390/v12090945
|
22 |
Junichi Shindoh, Kiyoshi Hasegawa, Yutaka Matsuyama, Yosuke Inoue, Takeaki Ishizawa, Taku Aoki, Yoshihiro Sakamoto, Yasuhiko Sugawara, Masatoshi Makuuchi, Norihiro Kokudo. Low Hepatitis C Viral Load Predicts Better Long-Term Outcomes in Patients Undergoing Resection of Hepatocellular Carcinoma Irrespective of Serologic Eradication of Hepatitis C Virus. Journal of Clinical Oncology 2013; 31(6): 766 doi: 10.1200/JCO.2012.44.3234
|
23 |
Jongduk Kwon, Kwang-Sik Chun, In-Sang Song, Seok-Hwan Kim, Sunjong Han. Long-term outcome of intraoperative radiofrequency ablation for hepatocellular carcinoma and its efficacy as a primary treatment. Annals of Hepato-Biliary-Pancreatic Surgery 2020; 24(1): 24 doi: 10.14701/ahbps.2020.24.1.24
|
24 |
C C N Chong, P B S Lai. Antiviral therapy after curative resection for patients with hepatitis B-related hepatocellular carcinoma. British Journal of Surgery 2013; 100(6): 724 doi: 10.1002/bjs.9105
|
25 |
Jian‐Bo Xu, Fu‐Zhen Qi, Gang Xu, Guo‐Feng Chen, Ming‐De Huang, Jian‐Huai Zhang. Adjuvant interferon therapy after surgical treatment for hepatitis B/C virus‐related hepatocellular carcinoma: A meta‐analysis. Hepatology Research 2014; 44(2): 209 doi: 10.1111/hepr.12109
|
26 |
Yiqi Yu, Jingwen Ai, Wenhong Zhang. Current clinical evidence for nucleos(t)ide analogues in patients with HBV-related hepatocellular carcinoma. Expert Review of Gastroenterology & Hepatology 2017; 11(10): 925 doi: 10.1080/17474124.2017.1343665
|
27 |
Young-Sun Lee, Yeon Seok Seo, Ji Hoon Kim, Juneyoung Lee, Hae Rim Kim, Yang Jae Yoo, Tae Suk Kim, Seong Hee Kang, Sang Jun Suh, Moon Kyung Joo, Young Kul Jung, Beom Jae Lee, Hyung Joon Yim, Jong Eun Yeon, Jae Seon Kim, Jong-Jae Park, Soon Ho Um, Young-Tae Bak, Kwan Soo Byun. Can More Aggressive Treatment Improve Prognosis in Patients with Hepatocellular Carcinoma? A Direct Comparison of the Hong Kong Liver Cancer and Barcelona Clinic Liver Cancer Algorithms. Gut and Liver 2018; 12(1): 94 doi: 10.5009/gnl17040
|
28 |
Xingshun Qi, Yan Zhao, Hongyu Li, Xiaozhong Guo, Guohong Han. Management of hepatocellular carcinoma: an overview of major findings from meta-analyses. Oncotarget 2016; 7(23): 34703 doi: 10.18632/oncotarget.9157
|
29 |
Chao-Wei Lee, Hsin-I Tsai, Chang-Mu Sung, Chun-Wei Chen, Shu-Wei Huang, Wen-Juei Jeng, Tsung-Han Wu, Kun-Ming Chan, Ming-Chin Yu, Wei-Chen Lee, Miin-Fu Chen. Risk factors for early mortality after hepatectomy for hepatocellular carcinoma. Medicine 2016; 95(39): e5028 doi: 10.1097/MD.0000000000005028
|
30 |
Enze Jiang, Anna Junjie Shangguan, Shuangshuang Chen, Lin Tang, Shuang Zhao, Zhenghong Yu. The progress and prospects of routine prophylactic antiviral treatment in hepatitis B-related hepatocellular carcinoma. Cancer Letters 2016; 379(2): 262 doi: 10.1016/j.canlet.2015.07.016
|
31 |
Tae Hyung Kim, Jung Mi Chang, Soon Ho Um, Heejung Jee, Yoo Ra Lee, Han Ah Lee, Sun Young Yim, Na Yeon Han, Jae Min Lee, Hyuk Soon Choi, Eun Sun Kim, Young-Dong Yu, Bora Keum, Min Ju Kim, Hyunggin An, Beom Jin Park, Yeon Seok Seo, Dong-Sik Kim, Hyung Joon Yim, Sung Bum Cho, Yoon Tae Jeen, Hong Sik Lee, Hoon Jai Chun, Yun Hwan Kim, Chang Duck Kim. Comparison of 2 curative treatment options for very early hepatocellular carcinoma. Medicine 2019; 98(26): e16279 doi: 10.1097/MD.0000000000016279
|
32 |
Zhi-Ming Zeng, Ning Mo, Jie Zeng, Fu-Chao Ma, Yan-Feng Jiang, Hua-Sheng Huang, Xi-Wen Liao, Guang-Zhi Zhu, Jie Ma, Tao Peng. Advances in postoperative adjuvant therapy for primary liver cancer. World Journal of Gastrointestinal Oncology 2022; 14(9): 1604-1621 doi: 10.4251/wjgo.v14.i9.1604
|
33 |
Jian-Hong Zhong, Qing-Lian Zhong, Le-Qun Li, Hang Li. Adjuvant and chemopreventive therapies for resectable hepatocellular carcinoma: a literature review. Tumor Biology 2014; 35(10): 9459 doi: 10.1007/s13277-014-2443-6
|
34 |
Xue Zhao, Zhen Yang, GuangBing Li, DongKai Li, Yi Zhao, Yan Wu, Simon C. Robson, Lian He, YiYao Xu, RuoYu Miao, HaiTao Zhao. The role and clinical implications of microRNAs in hepatocellular carcinoma. Science China Life Sciences 2012; 55(10): 906 doi: 10.1007/s11427-012-4384-x
|
35 |
Luigi Bolondi, Umberto Cillo, Massimo Colombo, Antonio Craxì, Fabio Farinati, Edoardo G. Giannini, Rita Golfieri, Massimo Levrero, Antonio Daniele Pinna, Fabio Piscaglia, Giovanni Raimondo, Franco Trevisani, Raffaele Bruno, Paolo Caraceni, Alessia Ciancio, Barbara Coco, Mirella Fraquelli, Maria Rendina, Giovanni Squadrito, Pierluigi Toniutto. Position paper of the Italian Association for the Study of the Liver (AISF): The multidisciplinary clinical approach to hepatocellular carcinoma. Digestive and Liver Disease 2013; 45(9): 712 doi: 10.1016/j.dld.2013.01.012
|
36 |
Grace Lai-Hung Wong, Ching-Ning Chong, Vincent Wai-Sun Wong. Tertiary Prevention of HBV-related HCC in Asia. Current Hepatitis Reports 2013; 12(3): 157 doi: 10.1007/s11901-013-0171-9
|
37 |
2014 Korean Liver Cancer Study Group-National Cancer Center Korea Practice Guideline for the Management of Hepatocellular Carcinoma. Korean Journal of Radiology 2015; 16(3): 465 doi: 10.3348/kjr.2015.16.3.465
|
38 |
Yan Du, Tong Su, Yibo Ding, Guangwen Cao. Effects of Antiviral Therapy on the Recurrence of Hepatocellular Carcinoma After Curative Resection or Liver Transplantation. Hepatitis Monthly 2012; 12(10) doi: 10.5812/hepatmon.6031
|
39 |
Feng Xia, Eric C. H. Lai, Wan-Yee Lau, Kuansheng Ma, Xiaowu Li, Ping Bie, Cheng Qian. High Serum Hyaluronic Acid and HBV Viral Load are Main Prognostic Factors of Local Recurrence after Complete Radiofrequency Ablation of Hepatitis B-Related Small Hepatocellular Carcinoma. Annals of Surgical Oncology 2012; 19(4): 1284 doi: 10.1245/s10434-011-2042-3
|
40 |
S. Petta, G. Cabibbo, M. Barbara, S. Attardo, L. Bucci, F. Farinati, E. G. Giannini, F. Tovoli, F. Ciccarese, G. L. Rapaccini, M. Di Marco, E. Caturelli, M. Zoli, F. Borzio, R. Sacco, R. Virdone, F. Marra, M. Felder, F. Morisco, L. Benvegnù, A. Gasbarrini, G. Svegliati‐Baroni, F. G. Foschi, A. Olivani, A. Masotto, G. Nardone, A. Colecchia, M. Persico, V. Boccaccio, A. Craxì, S. Bruno, F. Trevisani, C. Cammà. Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon. Alimentary Pharmacology & Therapeutics 2017; 45(1): 160 doi: 10.1111/apt.13821
|
41 |
Yue Zhao, Yuanyuan Jia, Sufen Qi, Chensi Wu, Jianhua Wu, Ruixing Zhang, Jing Li, Zhanjun Guo. Comparison of Postoperative Prognosis Among HBV-Related, HCV-Related, and Non-HBV Non-HCV Hepatocellular Carcinomas: A Systematic Review and Meta-analysis. Hepatitis Monthly 2022; 22(1) doi: 10.5812/hepatmon-121820
|
42 |
Bing Du, Shengmao Liu, Chengji Cui, Songyan Wang, Wenpeng Cui. Association between glucose transporter 1 rs841853 polymorphism and type 2 diabetes mellitus risk may be population specific (葡萄糖转移酶1的rs841853基因多态性与2型糖尿发生风险的关系可能具有人群特异性). Journal of Diabetes 2013; 5(3): 291 doi: 10.1111/1753-0407.12042
|
43 |
Tsuyoshi Kobayashi, Kohei Ishiyama, Hideki Ohdan. Prevention of recurrence after curative treatment for hepatocellular carcinoma. Surgery Today 2013; 43(12): 1347 doi: 10.1007/s00595-012-0473-5
|
44 |
T.‐S. Huang, Y.‐C. Shyu, H.‐Y. Chen, S.‐S. Yuan, J.‐N. Shih, P.‐J. Chen. A systematic review and meta‐analysis of adjuvant interferon therapy after curative treatment for patients with viral hepatitis‐related hepatocellular carcinoma. Journal of Viral Hepatitis 2013; 20(10): 729 doi: 10.1111/jvh.12096
|
45 |
Gui-Qi Zhu, Ke-Qing Shi, Hua-Jian Yu, Sun-Yue He, Martin Braddock, Meng-Tao Zhou, Yong-Ping Chen, Ming-Hua Zheng. Optimal adjuvant therapy for resected hepatocellular carcinoma: a systematic review with network meta-analysis. Oncotarget 2015; 6(20): 18151 doi: 10.18632/oncotarget.4098
|
46 |
Shi-Dong Lu, Lin Li, Xin-Min Liang, Wu Chen, Fu-Li Chen, Lang-Lin Fan, Bhavesh K. Ahir, Wan-Guang Zhang, Jian-Hong Zhong. Updates and advancements in the management of hepatocellular carcinoma patients after hepatectomy. Expert Review of Gastroenterology & Hepatology 2019; 13(11): 1077 doi: 10.1080/17474124.2019.1684898
|
47 |
Tae‐Se Kim, Dong Hyun Sinn, Wonseok Kang, Geum‐Youn Gwak, Yong‐Han Paik, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik. Hepatitis B virus DNA levels and overall survival in hepatitis B‐related hepatocellular carcinoma patients with low‐level viremia. Journal of Gastroenterology and Hepatology 2019; 34(11): 2028 doi: 10.1111/jgh.14750
|
48 |
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma. Clinical and Molecular Hepatology 2022; 28(4): 583 doi: 10.3350/cmh.2022.0294
|
49 |
Chiao-Fang Teng, Tsai-Chung Li, Hsi-Yuan Huang, Jia-Hui Lin, Wen-Shu Chen, Woei-Cherng Shyu, Han-Chieh Wu, Cheng-Yuan Peng, Ih-Jen Su, Long-Bin Jeng. Next-Generation Sequencing-Based Quantitative Detection of Hepatitis B Virus Pre-S Mutants in Plasma Predicts Hepatocellular Carcinoma Recurrence. Viruses 2020; 12(8): 796 doi: 10.3390/v12080796
|
50 |
Ting-Jung Wu, Shih-Shin Chang, Chia-Wei Li, Yi-Hsin Hsu, Tse-Ching Chen, Wei-Chen Lee, Chau-Ting Yeh, Mien-Chie Hung. Severe Hepatitis Promotes Hepatocellular Carcinoma Recurrence via NF-κB Pathway-Mediated Epithelial–Mesenchymal Transition after Resection. Clinical Cancer Research 2016; 22(7): 1800 doi: 10.1158/1078-0432.CCR-15-0780
|
51 |
Taro Takami, Takahiro Yamasaki, Issei Saeki, Toshihiko Matsumoto, Yutaka Suehiro, Isao Sakaida. Supportive therapies for prevention of hepatocellular carcinoma recurrence and preservation of liver function. World Journal of Gastroenterology 2016; 22(32): 7252-7263 doi: 10.3748/wjg.v22.i32.7252
|
52 |
HAO ZHANG, YUCHEN ZHOU, GUOSHENG YUAN, GUANGYAO ZHOU, DINGHUA YANG, YUANPING ZHOU. Antiviral therapy improves the survival rate and decreases recurrences and fatalities in liver cancer patients following curative resection: A meta-analysis. Molecular and Clinical Oncology 2015; 3(6): 1239 doi: 10.3892/mco.2015.614
|
53 |
Giuseppe Cabibbo, Salvatore Petta, Marco Barbàra, Gabriele Missale, Roberto Virdone, Eugenio Caturelli, Fabio Piscaglia, Filomena Morisco, Antonio Colecchia, Fabio Farinati, Edoardo Giannini, Franco Trevisani, Antonio Craxì, Massimo Colombo, Calogero Cammà. A meta‐analysis of single HCV‐untreated arm of studies evaluating outcomes after curative treatments of HCV‐related hepatocellular carcinoma. Liver International 2017; 37(8): 1157 doi: 10.1111/liv.13357
|
54 |
Li-Ping Chen, Jun Zhao, Yan Du, Yi-Fang Han, Tong Su, Hong-Wei Zhang, Guang-Wen Cao. Antiviral treatment to prevent chronic hepatitis B or C-related hepatocellular carcinoma. World Journal of Virology 2012; 1(6): 174-183 doi: 10.5501/wjv.v1.i6.174
|
55 |
Cristina Maria Muzica, Carol Stanciu, Laura Huiban, Ana-Maria Singeap, Catalin Sfarti, Sebastian Zenovia, Camelia Cojocariu, Anca Trifan. Hepatocellular carcinoma after direct-acting antiviral hepatitis C virus therapy: A debate near the end. World Journal of Gastroenterology 2020; 26(43): 6770-6781 doi: 10.3748/wjg.v26.i43.6770
|